Bayesian Sample Size Estimates in Clinical Trials with Dichotomous Outcomes
View Presentation *Boris G Zaslavsky, FDA Keywords: beta distribution, gamma distribution, hypothesis, posterior distribution, prior distribution, type I and II errors, power We use exact methods and Bayesian methodology. Our sample size estimations are based on power calculations under the one-sided alternative hypothesis that a new treatment is better than a control by a clinically important margin. The method resembles a standard frequentist problem formulation and, in the case of conjugate prior distributions with integer parameters, is similar to the frequentist approach. We evaluate type I and II errors through the use of credible limits in Bayesian models and through the use of confidence limits in frequentist models. Particularly, for conjugate priors with integer parameters, credible limits are identical to frequentist confidence limits with adjusted numbers of events and sample sizes. We consider conditions under which the minimal Bayesian sample size is less than the frequentist one and vice versa.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC